Head-to-head evidence
foslevodopa/foscarbidopa vs Levodopa-carbidopa intestinal gel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
foslevodopa/foscarbidopa · Vyalev
Marketed by AbbVie
NCT04380142 · Phase 3 · completed
The trial randomized 145 participants to active treatment or an active comparator, with participants, clinicians, investigators, and outcome assessors quadruple-blinded. The primary clinical endpoint was met: least-squares mean improvement in “On” time was 2.72 hours with ABBV-951 versus 0.97 hours with oral carbidopa/levodopa, a difference of 1.75 hours (95% CI 0.46–3.05; p=0.0083).
Levodopa-carbidopa intestinal gel · Duopa
Marketed by AbbVie
NCT00335153 · Phase 3 · completed
This was a 354-participant, open-label, single-group study with no randomization, blinding, or comparator arm. Its primary outcomes focused on safety and device complications, and there was no formal controlled primary efficacy comparison, so the reported secondary improvements do not establish treatment efficacy.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: foslevodopa/foscarbidopa's landscape · Levodopa-carbidopa intestinal gel's landscape